 |
市场调查报告书
商品编码
1149803
降血糖药市场：按药物类别、给药途径、分销渠道、地区 - 规模、份额、前景和机会分析，2022-2030 年Hypoglycemic Drugs Market, by Drug Class, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030 |
||||||
价格
简介目录
低血糖症是指血糖（葡萄糖）水平低于正常水平的情况。葡萄糖是身体的主要能量来源。低血糖通常与糖尿病治疗有关。当血液中的葡萄糖浓度低于设定点，即低于 4mmol/L (72mg/dL) 时，就会发生低血糖症。与低血糖相关的症状包括出汗、疲劳、头晕、虚弱和视力模糊。通过使用血糖仪测量血糖水平来检测低血糖症。血糖水平低于 4.0 mmol/L 表示低血糖。
市场动态
预计糖尿病患者数量的增加将推动全球降糖药市场的增长。例如，根据美国糖尿病协会 2022 年 7 月 28 日发表的一篇文章，2019 年有 3730 万美国人（占人口的 11.3%）患有糖尿病。约有 190 万美国人患有 1 型糖尿病，其中约有 244,000 人是儿童和青少年。每年有 140 万美国人被诊断患有糖尿病。根据同一个 Sorus 的数据，在 2014-2015 年，青少年中确诊糖尿病的年发病率估计为 18,200 例 1 型糖尿病和 5,800 例 2 型糖尿病。
监管机构批准的药物数量不断增加，预计将推动全球降糖药物市场的增长。例如，2020 年 12 月，专业製药公司 Anfastar Pharmaceuticals, Inc. 宣布美国食品药品监督管理局 (FDA) 已批准其胰高血糖素注射急救试剂盒 1mg 的简化新药申请。胰高血糖素适用于治疗严重的低血糖症，也可用作辅助诊断。
这项研究的主要特点
- 本报告对全球降糖药市场进行了深入分析，提供了以 2021 年为基准年的预测期 (2022-2030) 的市场规模和復合年增长率 (CAGR%)。.
- 它揭示了不同细分市场的潜在收入机会，并描述了该市场具有吸引力的投资建议矩阵。
- 它还提供了有关市场驱动因素、限制因素、机会、新药发布和批准、区域前景以及主要参与者采用的竞争战略的重要见解。
- 根据公司概况、业绩、产品组合、地域分布、分销战略、主要发展和战略以及未来计划等参数，对全球降糖药市场的主要参与者进行了概况分析。
- 本次调查涵盖的主要公司包括 Eli Lilly & Company、Boehringer Ingelheim GmbH、Vistin Pharma AS、Janssen Pharmaceuticals NV、Sanofi、Astellas Pharma Inc.、AstraZeneca plc.、Merck & Co., Inc.、Novartis AG、 Novo Nordisk A/S、Teva Pharmaceuticals Pvt Ltd. 和 Sun Pharmaceutical Industries Ltd.
- 这份报告中的见解将使公司的营销人员和管理人员能够就未来的产品发布、技术升级、市场扩张和营销策略做出明智的决策。
- 本研究报告面向该行业的各种利益相关者，包括投资者、供应商、製造商、分销商、新进入者和金融分析师。
- 利益相关者可以通过用于分析全球降糖药市场的各种战略矩阵来促进他们的决策。
内容
第 1 章目的和先决条件
- 调查目的
- 先决条件
- 缩写说明
第 2 章市场概述
- 报告内容
- 市场定义和范围
- 执行摘要
- 市场细分：按药物类别
- 按给药途径细分的市场
- 按分销渠道细分的市场
- 按地区划分的市场细分
- 连贯机会图 (COM)
第3章市场动态、规律及趋势分析
- 市场动态
- 司机
- 约束因素
- 市场机会
- 影响分析
- 分销商名单
- 主要发展状况
- 害虫分析
- 监管情景
- 新产品的发布和批准
- 收购和合作场景
- 市场趋势
第 4 章全球降糖药市场：冠状病毒 (COVID-19) 大流行的影响
- 经济影响
- COVID-19 的流行病学特征
- 供需分析
第 5 章全球降糖药市场：按药物类别分类，2017-2030
- 磺尿类
- 双胍类
- α-葡萄糖甘□抑製剂
- 塞唑烷二酮
- 二□基□□ 4 (DPP-4) 抑製剂
- 胰高血糖素
第 6 章全球降糖药市场：按给药途径，2017-2030
- 口服剂
- 注射
- 鼻音
第 7 章全球降糖药市场：分销渠道，2017-2030
- 医院药房
- 零售药房
- 在线药店
第 8 章按地区分列的全球降糖药市场，2017-2028
- 北美
- 美国
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲地区
- 欧洲
- 德国
- 英国
- 法国
- 意大利
- 西班牙
- 俄罗斯
- 其他欧洲地区
- 亚太地区
- 中国
- 印度
- 日本
- 澳大利亚
- 韩国
- 东盟
- 其他亚太地区
- 中东
- 海湾合作委员会
- 以色列
- 其他中东地区
- 非洲
- 南非
- 中非
- 北非
第9章竞争格局
- 公司简介
- Eli Lilly & Company
- Boehringer Ingelheim GmbH
- Vistin Pharma AS
- Janssen Pharmaceuticals NV
- Sanofi
- Astellas Pharma Inc.
- AstraZeneca plc.
- Merck & Co., Inc.
- Novartis AG
- Novo Nordisk A/S
- Teva Pharmaceutical Pvt. Ltd.
- Sun Pharmaceutical Industries Ltd.
第 10 章
- 参考资料
- 调查方法
简介目录
Product Code: CMI5252
Hypoglycemia is a condition in which blood sugar (glucose) level is lower than the standard range. Glucose is the main energy soiurce for the body. Hypoglycemia is often related to diabetes treatment. Hypoglycemia occurs when the level of glucose present in the blood falls below a set point, i.e., below 4 mmol/L (72mg/dL). The symptoms associated with Hypogyclemia are, sweating, fatigue, feeling dizzy, feeling weak, blurred vision, and others. Hypoglycemia is detected by measuring blood sugar levels with a glucose meter. Any blood glucose level below 4.0 mmol/L indicates that the individual has hypoglycemia.
Market Dynamics
Increasing prevalence of diabetes is expected to drive growth of the global hypoglycemic drugs market. For instance, according to an article published by American Diabetes Association on 28 July 2022, in 2019, 37.3 million Americans, or 11.3% of the population, had diabetes. Nearly 1.9 million Americans had type 1 diabetes, including about 244,000 children and adolescents. 1.4 million Americans are diagnosed with diabetes every year.according to same soruce, In 2014-2015, the annual incidence of diagnosed diabetes in youth was estimated at 18,200 with type 1 diabetes and 5,800 with type 2 diabetes.
Increasing number of drug approvals from regulatory bodies is expected to drive growth of the global hypoglycemic drugs market. For instance, in December 2020, Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved its Abbreviated New Drug Application for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid.
Key features of the study:
- This report provides an in-depth analysis of the global hypoglycemic drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global hypoglycemic drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
- Key companies covered as a part of this study include Eli Lilly & Company, Boehringer Ingelheim GmbH, Vistin Pharma AS, Janssen Pharmaceuticals NV, Sanofi, Astellas Pharma Inc., AstraZeneca plc., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Teva Pharmaceuticals Pvt Ltd., and Sun Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global hypoglycemic drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global hypoglycemic drugs market
Detailed Segmentation:
- Global Hypoglycemic Drugs Market, By Drug Class:
- Sulphonylureas
- Biguanides
- Alpha-glucosidase inhibitors
- Thiazolidinediones (Glitazones)
- Dipeptidyl peptidase-4 (DPP-4) inhibitors
- Glucagon
- Global Hypoglycemic Drugs Market, By Route of Administration:
- Oral
- Injectable
- Nasal
- Global Hypoglycemic Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Hypoglycemic Drugs Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- North America
- Company Profiles
- Eli Lilly & Company*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Boehringer Ingelheim GmbH
- Vistin Pharma AS
- Janssen Pharmaceuticals NV
- Sanofi
- Astellas Pharma Inc.
- AstraZeneca plc.
- Merck & Co., Inc.
- Novartis AG
- Novo Nordisk A/S
- Teva Pharmaceuticals Pvt Ltd.
- Sun Pharmaceutical Industries Ltd.
- Eli Lilly & Company*
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- List of Distributors
- Key Developments
- PEST Analysis
- Regulatory Scenario
- New Product Launch/ Approval
- Acquisition and Partnership Scenario
- Market Trends
4. Global Hypoglycemic Drugs Market - Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- COVID-19 Epidemiology
- Supply and Demand Analysis
5. Global Hypoglycemic Drugs Market, By Drug Class, 2017-2030 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Sulphonylureas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
- Biguanides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
- Alpha-glucosidase inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
- Thiazolidinediones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
- Dipeptidyl Peptidase-4 (DPP-4) inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
- Glucagon
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
6. Global Hypoglycemic Drugs Market, By Route of Administration, 2017-2030 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
- Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
7. Global Hypoglycemic Drugs Market, By Distribution Channel, 2017-2030 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
8. Global Hypoglycemic Drugs Market, By Region, 2017 - 2028 (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country/ Region, 2017 - 2030 (US$ Mn)
- South Africa
- Central Africa
- North Africa
9. Competitive Landscape
- Company Profiles
- Eli Lilly & Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Boehringer Ingelheim GmbH
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Vistin Pharma AS
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Janssen Pharmaceuticals NV
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Sanofi
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Astellas Pharma Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- AstraZeneca plc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Novo Nordisk A/S
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Teva Pharmaceutical Pvt. Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Analyst Views
10. Section
- References
- Research Methodology
- About Us and Sales Contact
